Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.
暂无分享,去创建一个
A. Edefonti | F. Scolari | P. Ravani | G. Ghiggeri | M. Bodria | A. Fornoni | R. Quinn | G. Montini | A. Bonanni | G. Barbano | R. Rossi | L. Murer | J. Reiser | A. Pasini | D. De Giovanni | F. Sica | M. Belingheri | Ludovica Degl'Innocenti
[1] J. Craig,et al. Corticosteroid therapy for nephrotic syndrome in children. , 2015, The Cochrane database of systematic reviews.
[2] S. Ito,et al. Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[3] R. Mori,et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial , 2014, The Lancet.
[4] M. Rudnicki,et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. , 2014, Journal of the American Society of Nephrology : JASN.
[5] J. Reiser,et al. Abatacept in B7-1-positive proteinuric kidney disease. , 2014, The New England journal of medicine.
[6] J. Goverman,et al. B Cells Promote Induction of Experimental Autoimmune Encephalomyelitis by Facilitating Reactivation of T Cells in the Central Nervous System , 2014, The Journal of Immunology.
[7] A. Edefonti,et al. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. , 2013, Kidney international.
[8] A. Vaglio,et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the art , 2013, Allergy.
[9] A. Anarat,et al. Circulating suPAR in two cohorts of primary FSGS. , 2012, Journal of the American Society of Nephrology : JASN.
[10] D. Cattran,et al. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient. , 2012, Kidney international.
[11] M. Suarez‐Almazor,et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. , 2012, JAMA.
[12] A. Edefonti,et al. Rituximab in children with resistant idiopathic nephrotic syndrome. , 2012, Journal of the American Society of Nephrology : JASN.
[13] W. Couser. Basic and translational concepts of immune-mediated glomerular diseases. , 2012, Journal of the American Society of Nephrology : JASN.
[14] L. Joosten,et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. , 2011, Arthritis and rheumatism.
[15] A. Edefonti,et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[16] Xia Li,et al. Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. , 2011, Clinical immunology.
[17] M. Rastaldi,et al. Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis , 2011, Science Translational Medicine.
[18] F. Cosio,et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[19] V. Savin,et al. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[20] C. Kallenberg. Pathophysiology of ANCA-Associated Small Vessel Vasculitis , 2010, Current rheumatology reports.
[21] G. Ghiggeri,et al. Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndrome , 2010, Clinical and experimental immunology.
[22] Akinori YamamotoKojiro,et al. Analysis of cytokine production patterns of peripheral blood mononuclear cells from a rheumatoid arthritis patient successfully treated with rituximab , 2010 .
[23] W. Oyen,et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[24] Susan L Furth,et al. New equations to estimate GFR in children with CKD. , 2009, Journal of the American Society of Nephrology : JASN.
[25] C. Usal,et al. Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. , 2009, Journal of the American Society of Nephrology : JASN.
[26] S. Amadori,et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. , 2008, Blood.
[27] D. Landau,et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. , 2008, Blood.
[28] J. Craig,et al. Corticosteroid therapy for nephrotic syndrome in children. , 2015, The Cochrane database of systematic reviews.
[29] T. Koike,et al. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non‐Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation , 2007, British journal of haematology.
[30] A. Theofilopoulos,et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. , 2007, Clinical immunology.
[31] L. Klareskog,et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. , 2007, Clinical immunology.
[32] G. Rizzoni,et al. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. , 2004, Clinical therapeutics.
[33] R. Kalluri,et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. , 2004, The Journal of clinical investigation.
[34] G. Ghiggeri,et al. Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[35] G. Filler. Treatment of nephrotic syndrome in children and controlled trials. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[36] J. Ingelfinger,et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). , 2000, Pediatrics.
[37] J B Carlin,et al. Sample-size calculation for a log-transformed outcome measure. , 1999, Controlled clinical trials.
[38] E. Lewis,et al. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[39] G. Schwartz,et al. A simple estimate of glomerular filtration rate in adolescent boys. , 1985, The Journal of pediatrics.
[40] R. White,et al. LONG-TERM OUTCOME FOR CHILDREN WITH MINIMAL-CHANGE NEPHROTIC SYNDROME , 1985, The Lancet.
[41] C. Ponticelli,et al. A Randomized Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy , 1984 .
[42] C. F. Strife,et al. Nephrotic syndrome in childhood. Management and treatment in patients with minimal change disease, mesangial proliferation, or focal glomerulosclerosis. , 1982, Pediatric clinics of North America.
[43] Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. , 1981, Kidney international.
[44] Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. , 1978, Kidney international.
[45] R. Shalhoub. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. , 1974, Lancet.
[46] B. Ramot,et al. POSSIBLE T-LYMPHOCYTE ORIGIN OF REED-STERNBERG CELLS , 1974 .